CN103110818B - Compound medicinal powder for burning and preparation method thereof - Google Patents
Compound medicinal powder for burning and preparation method thereof Download PDFInfo
- Publication number
- CN103110818B CN103110818B CN201210571147.7A CN201210571147A CN103110818B CN 103110818 B CN103110818 B CN 103110818B CN 201210571147 A CN201210571147 A CN 201210571147A CN 103110818 B CN103110818 B CN 103110818B
- Authority
- CN
- China
- Prior art keywords
- burn
- parts
- compound medicines
- powder
- dry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to the technical field of medicines, mainly relates to the technical field of a compound medicinal powder for burning and a preparation method thereof, and in particular relates to a compound medicinal powder for burning and a preparation method thereof. The compound medicinal powder for burning is prepared according to the following steps: step 1, weighing the following dry crude drugs in parts by weight: 80-120 parts of radix scutellariae, 40-80 parts of amur cork-tree bark, 40-80 parts of radix sanguisorbae, 10-30 parts of rhizoma bletillae and 100-300 parts of adjuvants; and step 2, mixing the radix sanguisorbae and the rhizoma bletillae to be crushed into 5 meshes and 50 meshes. The compound medicinal powder is simple and reasonable in extraction and preparation methods, and the pharmacological action is ensured through an extraction technology; the compound medicinal powder has an exact curative effect and less side effects, so that the pain of patients which is caused by changing dressings is greatly relieved; and the compound medicinal powder has the characteristics of convenience in use, high curative effect, short treatment course, quick effect and the like.
Description
Technical field
The present invention relates to medical art, relating generally to compound medicine and its preparation method technical field for the treatment of burn, is a kind of burn compound medicines and preparation method thereof.
Background technology
Burn and scald is a kind of acute injury caused because boiling water, steam, flame, chemical substance etc. directly act on body surface organization.Burn and scald is generally divided into three degree: first degree burn, only shows as red swelling of the skin, scorching hot, pain, does not have vesicle, do not stay cicatrix; Second degree burn, there is vesicle in skin, local is red and swollen, and sharp ache, treats general without large cicatrix in time; Third degree burn, the most seriously, infringement is dark, and skin is burned black, downright bad, and skeleton and blood vessel expose, and charrin's disease septicemia very easily occurs dead.Owing to there is the difficult problems such as wound pain, necrosis progrediens, easy infection, cicatrix healing in burn treating, if burned patient is treated not in time, the state of an illness is protracted course of disease often, some patients can change severe burn and scald into from slight burn and scald, very large misery can be brought to stay to patient, also can scar disabled etc.And western modern medicine treatment burn only need generally be sterilized to the requirement of burn wound, curative effect is low, takes effect slow.
Summary of the invention
The invention provides a kind of burn compound medicines and preparation method thereof, overcome the deficiency of above-mentioned prior art, it can effectively solve, and western modern medicine treatment burn curative effect is low, take effect slow problem.
One of technical scheme of the present invention is realized by following measures: a kind of burn compound medicines obtains in the steps below: the first step, another name of scoring by weight takes off states dry medical material, Radix Scutellariae 80 parts to 120 parts, Cortex Phellodendri 40 parts to 80 parts, Radix Sanguisorbae 40 parts to 80 parts, Pseudobulbus Bletillae (Rhizoma Bletillae) 10 parts to 30 parts, adjuvant 100 parts to 300 parts, second step, by Radix Sanguisorbae and Pseudobulbus Bletillae (Rhizoma Bletillae) co-grinding to 5 order to 50 order, aqueous solution is added wherein or 1% to 70% ethanol water floods as immersion solvent after pulverizing completes, flood 12 little after 72 hours, continue to add the aqueous solution of 5 times to 30 times that weight is the dry medical material gross weight of Radix Sanguisorbae and Pseudobulbus Bletillae (Rhizoma Bletillae) or 1% to 70% ethanol water carries out percolation, collect percolate, percolate is concentrated into 0.1 times of weight portion to 3 times weight portion of Radix Sanguisorbae and the dry medical material of Pseudobulbus Bletillae (Rhizoma Bletillae), dry extract I is obtained after concentrated solution is carried out drying, dry extract I is crushed to 100 order to 200 orders and obtains powder I, 3rd step, by Radix Scutellariae and Cortex Phellodendri co-grinding to 5 order to 50 order, add 20% to 95% ethanol water after pulverizing completes wherein to flood as immersion solvent, flood 12 little after 72 hours, continuing to add weight is that 20% to 95% ethanol water of 10 times to 40 times of the dry medical material gross weight of Radix Scutellariae and Cortex Phellodendri carries out percolation, collect percolate, percolate is concentrated into 0.1 times of weight portion to 3 times weight portion of Radix Scutellariae and the dry medical material of Cortex Phellodendri, obtain dry extract II after concentrated solution is carried out drying, dry extract II is crushed to 100 order to 200 orders and obtains powder II, 4th step, obtains mixed powder by powder I and powder II mix homogeneously, 5th step, after fully being mixed homogeneously by mixed powder, obtains burn compound medicines with the adjuvant taken in the first step.
Two of technical scheme of the present invention is realized by following measures: a kind of burn carries out in the steps below by polypharmaceutic preparation method: the first step, another name of scoring by weight takes off states dry medical material, Radix Scutellariae 80 parts to 120 parts, Cortex Phellodendri 40 parts to 80 parts, Radix Sanguisorbae 40 parts to 80 parts, Pseudobulbus Bletillae (Rhizoma Bletillae) 10 parts to 30 parts, adjuvant 100 parts to 300 parts, second step, by Radix Sanguisorbae and Pseudobulbus Bletillae (Rhizoma Bletillae) co-grinding to 5 order to 50 order, aqueous solution is added wherein or 1% to 70% ethanol water floods as immersion solvent after pulverizing completes, flood 12 little after 72 hours, continue to add the aqueous solution of 5 times to 30 times that weight is the dry medical material gross weight of Radix Sanguisorbae and Pseudobulbus Bletillae (Rhizoma Bletillae) or 1% to 70% ethanol water carries out percolation, collect percolate, percolate is concentrated into Radix Sanguisorbae and the dry medical material of Pseudobulbus Bletillae (Rhizoma Bletillae) 0.1 times of weight portion to 3 times weight portion, dry extract I is obtained after concentrated solution is carried out drying, dry extract I is crushed to 100 order to 200 orders and obtains powder I, 3rd step, by Radix Scutellariae and Cortex Phellodendri co-grinding to 5 order to 50 order, add 20% to 95% ethanol water after pulverizing completes wherein to flood as immersion solvent, flood 12 little after 72 hours, continuing to add weight is that 20% to 95% ethanol water of 10 times to 40 times of the dry medical material gross weight of Radix Scutellariae and Cortex Phellodendri carries out percolation, collect percolate, percolate is concentrated into 0.1 times of weight portion to 3 times weight portion of Radix Scutellariae and the dry medical material of Cortex Phellodendri, obtain dry extract II after concentrated solution is carried out drying, dry extract II is crushed to 100 order to 200 orders and obtains powder II, 4th step, obtains mixed powder by powder I and powder II mix homogeneously, 5th step, after fully being mixed homogeneously by mixed powder, obtains burn compound medicines with the adjuvant taken in the first step.
Here is the further optimization and/or improvements to foregoing invention technical scheme:
Above-mentioned adjuvant is carbomer, tragcanth, Polyethylene Glycol, sodium carboxymethyl cellulose, polyvinylpyrrolidone, hydroxypropyl emthylcellulose, hydroxypropyl cellulose, tristerin, glyceryl monostearate, stearic acid, tween 80, white vaseline, liquid paraffin, Cera Flava, triethanolamine, polyvinyl alcohol, arabic gum gelatin, glycerol, sodium benzoate, methyl hydroxybenzoate, ethyl hydroxybenzoate, propyl hydroxybenzoate, one in potassium sorbate, or wherein multiple by arbitrarily than the mixture of composition and above-mentioned two or more adjuvant by weight arbitrarily than the mixture formed.
Concentrated solution in above-mentioned second step obtains dry extract I after carrying out vacuum drying or spraying dry, and baking temperature is 40 DEG C to 150 DEG C.
Obtain dry extract II after concentrated solution in above-mentioned 3rd step carries out vacuum drying or spraying dry, baking temperature is 40 DEG C to 140 DEG C.
Above-mentioned burn compound medicines is made gel or ointment or membrane or powder.
Extraction of the present invention, preparation method are rationally easy, and ensure that the performance of its pharmacological action from extraction process, this compound medicines determined curative effect, few side effects, significantly reduce the misery of changing medicine for patient, and have easy to use, curative effect is high, short treating period, the features such as instant effect.
Detailed description of the invention
The present invention by the restriction of following embodiment, can not determine concrete embodiment according to technical scheme of the present invention and practical situation.
Below in conjunction with embodiment, the invention will be further described:
Embodiment 1, this burn compound medicines obtains by following preparation method: the first step, another name of scoring by weight takes off states dry medical material, Radix Scutellariae 80 parts to 120 parts, Cortex Phellodendri 40 parts to 80 parts, Radix Sanguisorbae 40 parts to 80 parts, Pseudobulbus Bletillae (Rhizoma Bletillae) 10 parts to 30 parts, adjuvant 100 parts to 300 parts, second step, by Radix Sanguisorbae and Pseudobulbus Bletillae (Rhizoma Bletillae) co-grinding to 5 order to 50 order, aqueous solution is added wherein or 1% to 70% ethanol water floods as immersion solvent after pulverizing completes, flood 12 little after 72 hours, continue to add the aqueous solution of 15 times to 30 times that weight is the dry medical material gross weight of Radix Sanguisorbae and Pseudobulbus Bletillae (Rhizoma Bletillae) or 1% to 70% ethanol water carries out percolation, collect percolate, percolate is concentrated into 0.1 times of weight portion to 3 times weight portion of Radix Sanguisorbae and the dry medical material of Pseudobulbus Bletillae (Rhizoma Bletillae), dry extract I is obtained after concentrated solution is carried out drying, dry extract I is crushed to 100 order to 200 orders and obtains powder I, 3rd step, by Radix Scutellariae and Cortex Phellodendri co-grinding to 5 order to 50 order, add 20% to 95% ethanol water after pulverizing completes wherein to flood as immersion solvent, flood 12 little after 72 hours, continuing to add weight is that 20% to 95% ethanol water of 10 times to 40 times of the dry medical material gross weight of Radix Scutellariae and Cortex Phellodendri carries out percolation, collect percolate, percolate is concentrated into 0.1 times of weight portion to 3 times weight portion of Radix Scutellariae and the dry medical material of Cortex Phellodendri, obtain dry extract II after concentrated solution is carried out drying, dry extract II is crushed to 100 order to 200 orders and obtains powder II, 4th step, obtains mixed powder by powder I and powder II mix homogeneously, 5th step, after fully being mixed homogeneously by mixed powder, obtains burn compound medicines with the adjuvant taken in the first step.
Embodiment 2, this burn compound medicines obtains by following preparation method: the first step, another name of scoring by weight takes off and states dry medical material, Radix Scutellariae 80 parts or 120 parts, Cortex Phellodendri 40 parts or 80 parts, Radix Sanguisorbae 40 parts or 80 parts, Pseudobulbus Bletillae (Rhizoma Bletillae) 10 parts or 30 parts, adjuvant 100 parts or 300 parts, second step, by Radix Sanguisorbae and Pseudobulbus Bletillae (Rhizoma Bletillae) co-grinding to 5 order or 50 orders, aqueous solution is added wherein or 1% or 70% ethanol water floods as immersion solvent after pulverizing completes, flood after 12 hours or 72 hours, continuing to add weight is that 15 times of the dry medical material gross weight of Radix Sanguisorbae and Pseudobulbus Bletillae (Rhizoma Bletillae) or the aqueous solution of 30 times or 1% or 70% ethanol water carry out percolation, collect percolate, percolate is concentrated into 0.1 times of weight portion to 3 times weight portion of Radix Sanguisorbae and the dry medical material of Pseudobulbus Bletillae (Rhizoma Bletillae), dry extract I is obtained after concentrated solution is carried out drying, dry extract I is crushed to 100 orders or 200 orders obtain powder I, 3rd step, by Radix Scutellariae and Cortex Phellodendri co-grinding to 5 order or 50 orders, add 20% or 95% ethanol water after pulverizing completes wherein to flood as immersion solvent, flood after 12 hours or 72 hours, to continue to add weight be 10 times of the dry medical material gross weight of Radix Scutellariae and Cortex Phellodendri or 40 times 20% or carry out percolation to 95% ethanol water, collect percolate, percolate is concentrated into 0.1 times of weight portion to 3 times weight portion of Radix Scutellariae and the dry medical material of Cortex Phellodendri, obtain dry extract II after concentrated solution is carried out drying, dry extract II is crushed to 100 orders or 200 orders obtain powder II, 4th step, obtains mixed powder by powder I and powder II mix homogeneously, 5th step, after fully being mixed homogeneously by mixed powder, obtains burn compound medicines with the adjuvant taken in the first step.
Embodiment 3, preferred as above-described embodiment, in the first step, counts by weight, Radix Scutellariae is 100 parts, Cortex Phellodendri is 60 parts, Radix Sanguisorbae is 60 parts, Pseudobulbus Bletillae (Rhizoma Bletillae) is 20 parts; In second step, by Radix Sanguisorbae and Pseudobulbus Bletillae (Rhizoma Bletillae) co-grinding to 20 order, add 50% ethanol water as immersion solvent, dip time is 48 hours, adding weight is that 50% ethanol water of 25 times of the dry medical material gross weight of Radix Sanguisorbae and Pseudobulbus Bletillae (Rhizoma Bletillae) carries out percolation, percolate is concentrated into 0.1 times of weight portion to 3 times weight portion of Radix Sanguisorbae and the dry medical material of Pseudobulbus Bletillae (Rhizoma Bletillae), dry extract I is crushed to 160 orders and obtains powder I; In 3rd step, by Radix Scutellariae and Cortex Phellodendri co-grinding to 20 order, add 50% ethanol water as immersion solvent, dip time is 48 hours, adding weight is that 50% ethanol water of 30 times of the dry medical material gross weight of Radix Scutellariae and Cortex Phellodendri carries out percolation, percolate is concentrated into 0.1 times of weight portion to 3 times weight portion of Radix Scutellariae and the dry medical material of Cortex Phellodendri, dry extract II is crushed to 160 orders and obtains powder II;
Embodiment 4, preferred as above-described embodiment, preferred as above-described embodiment, adjuvant is carbomer, tragcanth, Polyethylene Glycol, sodium carboxymethyl cellulose, polyvinylpyrrolidone, hydroxypropyl emthylcellulose, hydroxypropyl cellulose, tristerin, glyceryl monostearate, stearic acid, tween 80, white vaseline, liquid paraffin, Cera Flava, triethanolamine, polyvinyl alcohol, arabic gum gelatin, glycerol, sodium benzoate, methyl hydroxybenzoate, ethyl hydroxybenzoate, propyl hydroxybenzoate, one in potassium sorbate, or wherein multiple by weight arbitrarily than the mixture of composition and above-mentioned two or more adjuvant by weight arbitrarily than the mixture formed.
Embodiment 5, preferred as above-described embodiment, preferred as above-described embodiment, the concentrated solution in second step obtains dry extract I after carrying out vacuum drying or spraying dry, and baking temperature is 40 DEG C to 150 DEG C.
Embodiment 6, preferred as above-described embodiment, preferred as above-described embodiment, obtain dry extract II after the concentrated solution in the 3rd step carries out vacuum drying or spraying dry, baking temperature is 40 DEG C to 140 DEG C.
Embodiment 7, preferred as above-described embodiment, makes gel or ointment or membrane or powder by above-mentioned burn compound medicines.
One, get the burn compound medicines that above-described embodiment obtains and carry out analgesic experiment
1. experimental technique
1.1 hot plate method pain experiments
Get choosing pain reaction Kunming kind female mice 50 in 30 seconds that body weight is 18g to 22g, be divided into 5 groups at random.
Excipient control group: to be evenly coated with kind female mice right back toe back, first group of Kunming cotton swab with excipient and to touch excipient, the amount being coated with excipient is 25.6 g/kg;
Burn cream matched group: to be evenly coated with kind female mice right back toe back, second group of Kunming cotton swab by burn cream and to touch burn cream, the amount being coated with burn cream is 23.8 g/kg;
Burn compound medicines low dosage experimental group: the burn compound medicines obtained by the embodiment of the present invention is evenly coated with kind female mice right back toe back, the 3rd group of Kunming cotton swab and touches burn compound medicines, being coated with burn is 12.8g/kg by polypharmaceutic amount;
Dosage experiments group in burn compound medicines: the burn compound medicines obtained by the embodiment of the present invention is evenly coated with kind female mice right back toe back, the 4th group of Kunming cotton swab and touches burn compound medicines, being coated with burn is 25.6 g/kg by polypharmaceutic amount;
Burn compound medicines high dose experimental group: the burn compound medicines obtained by the embodiment of the present invention is evenly coated with kind female mice right back toe back, the 5th group of Kunming cotton swab and touches burn compound medicines, being coated with burn is 51.2 g/kg by polypharmaceutic amount.
Measure the pain threshold of every mice: be placed on by mice in large beaker, beaker be placed in be heated to 55 DEG C water-bath in, to lick metapedes for pain reaction index, beaker is dropped into the time of licking metapedes with stopwatch record mice, record the pain threshold of different time mice respectively, table 1 is the hot plate method pain threshold meansigma methods of each group of mice.
Writhing method
Getting body weight is 18g to 22g Kunming mouse 60, and male and female half and half, are divided into 5 groups at random.
Excipient control group: to be evenly coated with first group of Kunming mouse right back toe back cotton swab with excipient and to touch excipient, the amount being coated with excipient is 25.6 g/kg;
Burn cream matched group: to be evenly coated with second group of Kunming mouse right back toe back cotton swab by burn cream and to touch burn cream, the amount being coated with burn cream is 23.8 g/kg;
Burn compound medicines low dosage experimental group: the burn compound medicines obtained by the embodiment of the present invention is evenly coated with the 3rd group of Kunming mouse right back toe back cotton swab and touches burn compound medicines, being coated with burn is 12.8g/kg by polypharmaceutic amount;
Dosage experiments group in burn compound medicines: the burn compound medicines obtained by the embodiment of the present invention is evenly coated with the 4th group of Kunming mouse right back toe back cotton swab and touches burn compound medicines, being coated with burn is 25.6 g/kg by polypharmaceutic amount;
Burn compound medicines high dose experimental group: the burn compound medicines obtained by the embodiment of the present invention is evenly coated with the 5th group of Kunming mouse right back toe back cotton swab and touches burn compound medicines, being coated with burn is 51.2 g/kg by polypharmaceutic amount.
After minute, respectively to the mouse peritoneal injection glacial acetic acid solution of each group, the glacial acetic acid solution of every injected in mice 0.2ml, 6g/L, record writhing number of times in every mice 10min: occur that abdominal part indent, trunk and hind leg are upheld with mice, buttocks is raised and is counted index, and table 2 is the writhing method writhing number of times meansigma methods of each group of mice.
Statistical analysis
Experimental data all adopt mean+SD (
± s) represent, carry out statistical procedures, P<0.05 with t inspection.Represent that difference has statistical significance.
Interpretation
3.1 impacts on the threshold of pain, hot plate method in mice analgesic test
As shown in Table 1, compare with excipient control group, the pain threshold of the high, medium and low dosage group of the burn compound medicines equal energy significant prolongation mice that burn cream group and the embodiment of the present invention obtain, the each group of effect of the threshold of pain that is all significantly improved after 1h, after 2h, burn cream group and senior middle school's dosage group still have effect, but relatively little, and after 3h, burn cream group and senior middle school's dosage still have effect, and other several groups all have no significant effect, high dose group and burn cream group improve threshold of pain effect quite.
On the impact of mouse writhing method test writhing number of times
As shown in Table 2, compare with excipient control group, high, medium and low group of the burn compound medicines that burn cream group and the embodiment of the present invention obtain all significantly can reduce the writhing number of times of mice, compares P<0.01 or P<0.05 with vehicle group.
Discuss
Hot plate method in mice and writhing method analgesic experiment result show, this medicine to physical property, the chemical induced pain factor is pain caused obvious analgesic activity, onset is very fast, and action time is longer, and analgesic activity strengthens with the increase of dosage.
Two, get the burn compound medicines that above-described embodiment obtains and carry out antiinflammatory experiment
1. experimental technique
1. rat Ovum Gallus domesticus album causes pedal swelling test
Getting body weight is 180g to 220g wistar rat 60, and male and female half and half, are divided into 5 groups at random, first measures and often organize every rat right hind leg ankle joint perimeter value before experiment, and this value is girth normal value before experiment.
Excipient control group: every rat is poured water 4ml, be coated with excipient every 15min in right hind ankle, totally 3 times, then only cause inflammation in this place subcutaneous injection fresh albumen 0.05ml/, and repaste excipient 4 times after Yu Zhiyan in lh, to be coated with excipient total amount be 25.6 g/kg;
Burn cream matched group: every rat is poured water 4ml, be coated with burn cream every 15min in right hind ankle, totally 3 times, then only cause inflammation in this place subcutaneous injection fresh albumen 0.05ml/, and repaste burn cream 4 times after Yu Zhiyan in lh, to be coated with burn cream total amount be 23.8 g/kg;
Burn compound medicines low dosage experimental group: every rat is poured water 4ml, the burn compound medicines of embodiment of the present invention acquisition is coated with in right hind ankle every 15min, totally 3 times, then only inflammation is caused in this place subcutaneous injection fresh albumen 0.05ml/, and after Yu Zhiyan, in lh, repasting the burn compound medicines 4 times that the embodiment of the present invention obtains, the burn compound medicines total amount that institute is coated with embodiment of the present invention acquisition is 12.8 g/kg;
Dosage experiments group in burn compound medicines: every rat is poured water 4ml, the burn compound medicines of embodiment of the present invention acquisition is coated with in right hind ankle every 15min, totally 3 times, then only inflammation is caused in this place subcutaneous injection fresh albumen 0.05ml/, and after Yu Zhiyan, in lh, repasting the burn compound medicines 4 times that the embodiment of the present invention obtains, the burn compound medicines total amount that institute is coated with embodiment of the present invention acquisition is 25.6 g/kg;
Burn compound medicines high dose experimental group: every rat is poured water 4ml, the burn compound medicines of embodiment of the present invention acquisition is coated with in right hind ankle every 15min, totally 3 times, then only inflammation is caused in this place subcutaneous injection fresh albumen 0.05ml/, and after Yu Zhiyan, in lh, repasting the burn compound medicines 4 times that the embodiment of the present invention obtains, the burn compound medicines total amount that institute is coated with embodiment of the present invention acquisition is 51.2 g/kg;
Respectively at cause scorching after 1h, 2h, 3h measure the ankle joint girth of each group of every rat, causing the difference of girth normal value before the girth after inflammation and experiment is swelling degree, and table 3 causes pedal swelling level average values for each group of rat Ovum Gallus domesticus album.
Mice caused by dimethylbenzene xylene ear swelling is tested
Getting body weight is 18g to 22g Kunming mouse 60, and male and female half and half, are divided into 5 groups at random.
Excipient control group: to the auris dextra cotton swab uniform application excipient of every mice, 30 min two sided coatings proinflammatory agent dimethylbenzene 0.02mL/ altogether before and after animal subject auris dextra after last administration, left ear is left intact, to be coated with excipient total amount be 25.6 g/kg;
Burn cream matched group: to the auris dextra cotton swab uniform application burn cream of every mice, 30 min two sided coatings proinflammatory agent dimethylbenzene 0.02mL/ altogether before and after animal subject auris dextra after last administration, left ear is left intact, to be coated with burn cream total amount be 23.8 g/kg;
Burn compound medicines low dosage experimental group: the burn compound medicines that the auris dextra of every mice is obtained by the cotton swab uniform application embodiment of the present invention, 30 min two sided coatings proinflammatory agent dimethylbenzene 0.02mL/ altogether before and after animal subject auris dextra after last administration, left ear is left intact, be coated with the embodiment of the present invention obtain burn compound medicines total amount be 12.8 g/kg;
Dosage experiments group in burn compound medicines: the burn compound medicines that the auris dextra of every mice is obtained by the cotton swab uniform application embodiment of the present invention, 30 min two sided coatings proinflammatory agent dimethylbenzene 0.02mL/ altogether before and after animal subject auris dextra after last administration, left ear is left intact, be coated with the embodiment of the present invention obtain burn compound medicines total amount be 25.6 g/kg;
Burn compound medicines high dose experimental group: the burn compound medicines that the auris dextra of every mice is obtained by the cotton swab uniform application embodiment of the present invention, 30 min two sided coatings proinflammatory agent dimethylbenzene 0.02mL/ altogether before and after animal subject auris dextra after last administration, left ear is left intact, be coated with the embodiment of the present invention obtain burn compound medicines total amount be 51.2 g/kg;
After 1 hour, every mice takes off cervical vertebra execution, cut ears along auricle baseline, take off auricle respectively weigh with diameter 7mm card punch at the symmetrical position of left and right ear, recording its weight difference is ear thickness, more each group difference, table 4 is the meansigma methods of mice caused by dimethylbenzene xylene ear thickness.
Statistical analysis
Experimental data all adopt mean+SD (
± s) represent, carry out statistical procedures, P<0.05 with t inspection.Represent that difference has statistical significance.
Interpretation
4.1 cause the impact of pedal swelling to rat Ovum Gallus domesticus album
As shown in Table 3, compare with vehicle group, the burn compound medicines high, medium and low dosage group that burn cream group and the embodiment of the present invention obtain all can cause rat hindlimb ankle swelling to Ovum Gallus domesticus album obvious inhibitory action, and high dose has obvious and lasting inhibitory action and before 2h clearly.
Xylol causes the impact of mice ear
From table 4, result shows, compared with vehicle group, each medication group ear edema has obvious inhibitory action, two auricle weight differences change obviously compared with blank group, the burn compound medicines high dose group P<0.05 that the embodiment of the present invention obtains, substantially close with the antiinflammatory intensity of burn cream group, the embodiment of the present invention obtain burn compound medicines in, low dose group P<0.05, show that its inhibitory rate of intumesce strengthens with dosage escalation.
Discuss
Burnt degree skin outer layer defensive barrier is destroyed, impaired place organizational structure changes, and capillary endothelium basement membrane permeability changes, and endovascular blood plasma sample liquid body infiltrates interstice or wound surface very soon, formative tissue edema transudate or blister, and then produce acute inflammatory reaction.Due to the early stage main manifestations of inflammatory reaction of burn be telangiectasis, permeability is hyperfunction, ooze out and edema, have selected with swelling is the Earlier period of inflammation experimental technique of leading indicator, mensuration causes scorching front and back edema degree, inquires into the polypharmaceutic antiinflammatory action of burn that the embodiment of the present invention obtains.Mouse auricle swelling test result shows, the auricle edema that the burn compound medicines that the embodiment of the present invention obtains can suppress mice caused by dimethylbenzene xylene otitis to occur significantly, xylol causes scorching suppression ratio and is greater than 40%, compares have significant differences (P<0.01) with vehicle group.
Three, get the burn compound medicines that above-described embodiment obtains and carry out wound healing experiment
1. experimental technique
Get body weight 18-22 g Kunming mouse 70, all mices 24 hours on pretreatment, every mice cuts off back wool, then mouse back spinal column two lateral areas is coated in 40 DEG C of warm depilatory, depilation area about 4cm × 6cm, cleans with clear water after 5-10min, observes 24h, determine that depilation position is without abnormal conditions such as redness, inflammation and breakages, is then divided into 7 groups at random.
Adopt ether light anaesthesia by after every mice 24h of the 2nd group to the 7th group, be placed on operating board, 75% ethanol disinfection test block skin; Separately the aluminium pan filling water is placed on electric furnace, and the counterweight of 20g is placed in pot is together heated to boil, maintain 10min; Then clamp counterweight upper end with pliers, be placed on rapidly 5s on mice depilation district skin, and pressure a little, the light degree Ⅱ scalding model that scalding area is 2cm × 2cm can be formed.After scald, local skin is porcelain white, and epidermis shows shrinkage, and common local skin has diabrosis, and normal region is clear and legible with scald position, and scald 4h subendothelial tissue edema is obvious.
Normal group: getting first group is Normal group, every mice is often average daily smears normal saline 0.25ml in depilation district, back, smears 2 every day, and each 1 time sooner or later, smear normal saline 15d continuously, single cage is raised;
Model control group: getting second group is model control group, every mice is often average daily smears normal saline 0.25ml in depilation district, back, smears 2 every day, and each 1 time sooner or later, smear normal saline 15d continuously, single cage is raised;
Excipient control group: getting the 3rd group is excipient control group, every mice is often average daily smears excipient in depilation district, back, smears 2 every day, and each 1 time sooner or later, each amount of excipient is 25.6 g/kg, smears excipient 15d continuously, and single cage is raised;
Burn cream matched group: getting the 4th group is burn cream matched group, every mice is often average daily smears burn cream in depilation district, back, smears 2 every day, and each 1 time sooner or later, each burn cream consumption is 23.8 g/kg, smears burn cream 15d continuously, and single cage is raised;
Burn compound medicines low dosage experimental group: getting the 5th group is burn compound medicines low dosage experimental group, every mice often average daily burn compound medicines smeared the embodiment of the present invention in depilation district, back and obtain, smear 2 every day, sooner or later each 1 time, the burn compound medicines that each embodiment of the present invention obtains is 12.8 g/kg, the burn compound medicines 15d that the continuous embodiment of the present invention obtains, single cage is raised;
Dosage experiments group in burn compound medicines: getting the 5th group is burn compound medicines low dosage experimental group, every mice often average daily burn compound medicines smeared the embodiment of the present invention in depilation district, back and obtain, smear 2 every day, sooner or later each 1 time, the burn compound medicines that each embodiment of the present invention obtains is 25.6 g/kg, the burn compound medicines 15d that the continuous embodiment of the present invention obtains, single cage is raised;
Burn compound medicines high dose experimental group: getting the 5th group is burn compound medicines low dosage experimental group, every mice often average daily burn compound medicines smeared the embodiment of the present invention in depilation district, back and obtain, smear 2 every day, sooner or later each 1 time, the burn compound medicines that each embodiment of the present invention obtains is 51.2 g/kg, the burn compound medicines 15d that the continuous embodiment of the present invention obtains, single cage is raised;
2. wound healing time and healing rate evaluation
Observe wound healing time and Wound healing rate every day.Wound healing criterion: wound surface decrustation, new epithelium generates, respectively at 3 days, 6 days, 9 days, 12 days, 15 days with vernier caliper measurement wound surface lengthwise with grow crosswise, by ellipse area formulae discovery wound area.Each treated animal wound healing number during record experiment the 15th day, calculates the average healing days of each treated animal wound surface (when 15 days, non-healing person was by calculating in 15 days).Table 5 is each group of wounds in mice healing rate meansigma methods and the average healing days meansigma methods of wound surface.
Long-pending before Wound healing rate=(long-pending after long-pending-medication before medication)/medication
3. tissue of burn pathological observation
After last medication lh, cervical dislocation puts to death mice, burn wound is taken off in the lump together with surrounding skin, is laid on filter paper, is then placed in freshly prepared BouinShi with determining liquid.Routinely paraffin wax flaking method carry out that dehydration is transparent, paraffin embedding, section, slice thickness is 4-6 m, hematoxylin-eosin staining (HE dyeing).Microscopic examination.
Statistical procedures
Experimental data all adopt mean+SD (
± s) represent, carry out statistical procedures, P<0.05 with t inspection.Represent that difference has statistical significance.
Interpretation
5.1 each groups of impacts on burned mouse wound surface the average healing and healing rate
From table 5, result shows, along with the continued treatment of each group of medicine, each group of animal subject scald wound scald wound incrustation area progressively reduces, healing rate significantly rises, compared with model control group group, the high, medium and low dosage group of burn compound medicines that burn cream matched group and the embodiment of the present invention obtain, difference is very significantly (P<0.01); And the average healing also obviously shortens (P<0.01), wherein with burn compound medicines high dose experimental group best results.Illustrate that the burn compound medicines that the embodiment of the present invention obtains has certain facilitation to burned mouse wound repair.The burn compound medicines promoting healing effect that the embodiment of the present invention obtains is better than burn cream.The results are shown in Table 5.
Burn cream is on the impact of burned mouse dermal pathology form
Normal group mouse skin epidermis cell marshalling, continuously, to be methodically arranged; Nucleus and kytoplasm well painted.Karyon is positioned at central authorities mostly; Skin corium tissue and accessory organ's clear in structure thereof, complete.Model control group mouse skin is scalded the early stage visible epidermis cell of planing surface and is mostly come off, structural fuzzy, wall regeneration, and some epidermises have obvious longitudinal crack, and the tired necrosis of the epidermal area also had is formed uneven; Cell in skin corium disappears mostly, and in empty shape, collagen fiber are in fracture shape, mottled or random shape, and thickness obviously reduces.And burn compound medicines each dosage group mice that burn cream matched group and the embodiment of the present invention obtain is through continuous 15d exterior coating treatment, compare with model control group, visible epidermis and dermis are organized and are all improved significantly.The burn compound medicines low dose group mouse skin epidermis that wherein embodiment of the present invention obtains still has more necrotic zone, and space and slight crack are still obvious, but more far better than model control group form, and collagen fiber are the arrangement of longitudinal bunchy; The skin epidermis clear in structure of dosage treated animal in the burn compound medicines that the embodiment of the present invention obtains, wound face recovers very fast, but the collagen fiber in corium still have fracture; Burn compound medicines high dose group and burn cream treated animal epiderm skin clear in structure that the embodiment of the present invention obtains, cellular morphology recovers good, and the arrangement of collagen fibers in dermal tissue is clear, without dissolving or mixed and disorderly phenomenon, compares no significant difference with matched group.The burn compound medicines that the result prompting embodiment of the present invention obtains has obvious therapeutical effect to scalded skin.
Discuss
From scalded skin in appearance, after scalding, mouse skin all has destruction in various degree in early days from epidermal area to skin corium.Main manifestations is that epidermal layer cells and accessory organ's cellularity have hyperemia, edema and necrosis phenomena, and skin corium clear cell disappears mostly, and arrangement of collagen fibers is mixed and disorderly or rupture.Later stage scalded skin keratinization of epidermis thickens and forms a scab.Some local bring out infection with microorganism through wound surface intrusion.Arrangement of collagen fibers in skin corium is unordered or rupture, and compare with normal group, thickness obviously reduces.After the burn compound medicines 15d that the outer embodiment of the present invention obtains continuously.Find that it can improve the healing rate of scalded skin significantly, shorten the time of wound healing.PATHOMORPHOLOGICAL OBSERVATION OF PULLORUM finds, this product also can accelerate reparation and the renewal of the Skin Cell after scalding, remove cell and the harmful substance thereof of degeneration or apoptosis, promote the generation of the neovascularity of scalding local, after finding the treatment of application burn cream, mice scalded skin does not find that there is obvious inflammation simultaneously yet.The burn compound medicines that the embodiment of the present invention obtains has good repair to scalded skin wound healing.
In a word, this medical instrument has obvious analgesia, antiinflammatory and wound healing effect, be a kind of be applicable to treat in, the II degree of small size burn, the external preparation of scalding, this medicine is without any side effects, easy and simple to handle, economical, be more suitable for basic unit promote and family respectively use.This experiment, for determining that its clinical efficacy provides foundation, shows the application prospect that this medicine is good.
The hot plate method pain threshold meansigma methods of mice respectively organized by table 1
| Group | The front threshold of pain (s) of administration | The threshold of pain (s) after 1h administration | The threshold of pain (s) after 2h administration | The threshold of pain (s) after 3h administration |
| Excipient control group | 17.7±1.2 | 20.5±2.4 | 20.8±1.4 | 19.8±2.5 |
| Burn cream matched group | 17.1±1.3 | 43.2±2.0** | 47.5±1.5** | 47.2±0.9* |
| Burn compound medicines low dosage experimental group | 17.3±2.1 | 37.9±2.6* | 35.0±1.5* | 32.7±1.1* |
| Dosage experiments group in burn compound medicines | 18.5±1.4 | 38.0±2.4* | 37.7±2.0* | 31.0±1.1 |
| Burn compound medicines high dose experimental group | 17.7±2.2 | 42.7±2.0** | 47.2±1.7** | 47.4±0.5** |
Note: excipient control group *: P <0.05, * *: P<0.01
The writhing method writhing number of times meansigma methods of mice respectively organized by table 2
| Group | Writhing number of times |
| Excipient control group | 20.5±2.4 |
| Burn cream matched group | 7.9±2.8** |
| Burn compound medicines low dosage experimental group | 11.4±2.9* |
| Dosage experiments group in burn compound medicines | 9.8±3.3** |
| Burn compound medicines high dose experimental group | 8.80±3.0** |
Note: excipient control group *: P <0.05, * *: P<0.01
Table 3 respectively group rat Ovum Gallus domesticus album causes pedal swelling level average values
| Group | Cause scorching rear 1h | Cause scorching rear 2h | Cause scorching rear 3h |
| Excipient control group | 7.5±2.0 | 8.2±1.4 | 7.7±1.0 |
| Burn cream matched group | 5.4±2.2** | 5.0±1.9** | 4.9±1.9* |
| Burn compound medicines low dosage experimental group | 6.4±1.0* | 5.9±2.1* | 6.1±1.2* |
| Dosage experiments group in burn compound medicines | 6.1±2.5* | 6.1±1.8* | 6.0±1.4* |
| Burn compound medicines high dose experimental group | 5.6±2.0** | 5.0±1.3** | 4.9±1.7** |
Note: excipient control group *: P <0.05, * *: P<0.01
The meansigma methods of table 4 mice caused by dimethylbenzene xylene ear thickness
| Group | Swelling (mg) | Inhibitory rate of intumesce (%) |
| Excipient control group | 5.9±1.8 | - |
| Burn cream matched group | 3.4±2.2** | 42.4 |
| Burn compound medicines low dosage experimental group | 4.8±1.2* | 18.6 |
| Dosage experiments group in burn compound medicines | 4.5±2.3* | 23.7 |
| Burn compound medicines high dose experimental group | 3.4±1.9** | 42.4 |
Note: excipient control group *: P <0.05, * *: P<0.01
Table 5 is group wounds in mice healing rate meansigma methods and the average healing days meansigma methods of wound surface respectively
| Group | Healing rate (%) 3 | Healing rate (%) 6 | Healing rate (%) 9 | Healing rate (%) 12 | Healing rate (%) 15 | Average healing days (my god) |
| Normal group | - | - | - | - | - | - |
| Model control group | 20.3±10.3 | 29.8±10.7 | 39.0±13.4 | 49.5±15.1 | 56.5±19.9 | 14.3±0.6 |
| Excipient control group | 26.8±11.4 | 35.5±12.4 | 41.0±14.8 | 58.5±17.6 | 65.2±18.3* | 13.8±0.8 |
| Burn cream matched group | 48.3±17.0 | 54.7±11.3 | 65.8±14.2** | 83.2±14.0 | 93.2±5.3** | 9.51±1.0** |
| Burn compound medicines low dosage experimental group | 43.1±14.3 | 50.2±11.5 | 57.6±9.5 | 73.8±13.5* | 84.3±15.4* | 11.2±1.4 |
| Dosage experiments group in burn compound medicines | 46.9±13.7 | 52.0±12.0 | 58.1±8.9* | 76.5±18.1* | 88.6±12.9** | 10.5±1.5* |
| Burn compound medicines high dose experimental group | 48.1±15.5 | 53.8±10.9 | 61.7±12.8* | 79.0±11.4* | 94.2±7.2** | 9.20±1.2** |
Note: excipient control group *: P <0.05, * *: P<0.01
Claims (17)
1. a burn compound medicines, it is characterized in that obtaining in the steps below: the first step, another name of scoring by weight takes off states dry medical material, Radix Scutellariae 80 parts to 120 parts, Cortex Phellodendri 40 parts to 80 parts, Radix Sanguisorbae 40 parts to 80 parts, Pseudobulbus Bletillae (Rhizoma Bletillae) 10 parts to 30 parts, adjuvant 100 parts to 300 parts, second step, by Radix Sanguisorbae and Pseudobulbus Bletillae (Rhizoma Bletillae) co-grinding to 5 order to 50 order, aqueous solution is added wherein or 1% to 70% ethanol water floods as immersion solvent after pulverizing completes, flood 12 little after 72 hours, continue to add the aqueous solution of 5 times to 30 times that weight is the dry medical material gross weight of Radix Sanguisorbae and Pseudobulbus Bletillae (Rhizoma Bletillae) or 1% to 70% ethanol water carries out percolation, collect percolate, percolate is concentrated into 0.1 times of weight portion to 3 times weight portion of Radix Sanguisorbae and the dry medical material of Pseudobulbus Bletillae (Rhizoma Bletillae), dry extract I is obtained after concentrated solution is carried out drying, dry extract I is crushed to 100 order to 200 orders and obtains powder I, 3rd step, by Radix Scutellariae and Cortex Phellodendri co-grinding to 5 order to 50 order, add 20% to 95% ethanol water after pulverizing completes wherein to flood as immersion solvent, flood 12 little after 72 hours, continuing to add weight is that 20% to 95% ethanol water of 10 times to 40 times of the dry medical material gross weight of Radix Scutellariae and Cortex Phellodendri carries out percolation, collect percolate, percolate is concentrated into 0.1 times of weight portion to 2 times weight portion of Radix Scutellariae and the dry medical material of Cortex Phellodendri, obtain dry extract II after concentrated solution is carried out drying, dry extract II is crushed to 100 order to 200 orders and obtains powder II, 4th step, obtains mixed powder by powder I and powder II mix homogeneously, 5th step, after fully being mixed homogeneously by mixed powder, obtains burn compound medicines with the adjuvant taken in the first step.
2. burn compound medicines according to claim 1, is characterized in that adjuvant is that one or more in carbomer, tragcanth, Polyethylene Glycol, sodium carboxymethyl cellulose, polyvinylpyrrolidone, hydroxypropyl emthylcellulose, hydroxypropyl cellulose, tristerin, glyceryl monostearate, stearic acid, tween 80, white vaseline, liquid paraffin, Cera Flava, triethanolamine, polyvinyl alcohol, arabic gum gelatin, glycerol, sodium benzoate, methyl hydroxybenzoate, ethyl hydroxybenzoate, propyl hydroxybenzoate, potassium sorbate are by arbitrarily than the mixture formed.
3. burn compound medicines according to claim 1 and 2, obtain dry extract I after the concentrated solution that it is characterized in that in second step carries out vacuum drying or spraying dry, baking temperature is 40 DEG C to 150 DEG C.
4. burn compound medicines according to claim 1 and 2, obtain dry extract II after the concentrated solution that it is characterized in that in the 3rd step carries out vacuum drying or spraying dry, baking temperature is 40 DEG C to 140 DEG C.
5. burn compound medicines according to claim 3, obtain dry extract II after the concentrated solution that it is characterized in that in the 3rd step carries out vacuum drying or spraying dry, baking temperature is 40 DEG C to 140 DEG C.
6. burn compound medicines according to claim 1 and 2, is characterized in that this burn compound medicines to make gel or ointment or membrane or powder.
7. burn compound medicines according to claim 3, is characterized in that this burn compound medicines to make gel or ointment or membrane or powder.
8. burn compound medicines according to claim 4, is characterized in that this burn compound medicines to make gel or ointment or membrane or powder.
9. burn compound medicines according to claim 5, is characterized in that this burn compound medicines to make gel or ointment or membrane or powder.
10. a burn uses polypharmaceutic preparation method, it is characterized in that carrying out in the steps below: the first step, another name of scoring by weight takes off states dry medical material, Radix Scutellariae 80 parts to 120 parts, Cortex Phellodendri 40 parts to 80 parts, Radix Sanguisorbae 40 parts to 80 parts, Pseudobulbus Bletillae (Rhizoma Bletillae) 10 parts to 30 parts, adjuvant 100 parts to 300 parts, second step, by Radix Sanguisorbae and Pseudobulbus Bletillae (Rhizoma Bletillae) co-grinding to 5 order to 50 order, aqueous solution is added wherein or 1% to 70% ethanol water floods as immersion solvent after pulverizing completes, flood 12 little after 72 hours, continue to add the aqueous solution of 5 times to 30 times that weight is the dry medical material gross weight of Radix Sanguisorbae and Pseudobulbus Bletillae (Rhizoma Bletillae) or 1% to 70% ethanol water carries out percolation, collect percolate, percolate is concentrated into 0.1 times of weight portion to 3 times weight portion of Radix Sanguisorbae and the dry medical material of Pseudobulbus Bletillae (Rhizoma Bletillae), dry extract I is obtained after concentrated solution is carried out drying, dry extract I is crushed to 100 order to 200 orders and obtains powder I, 3rd step, by Radix Scutellariae and Cortex Phellodendri co-grinding to 5 order to 50 order, add 20% to 95% ethanol water after pulverizing completes wherein to flood as immersion solvent, flood 12 little after 72 hours, continuing to add weight is that 20% to 95% ethanol water of 10 times to 40 times of the dry medical material gross weight of Radix Scutellariae and Cortex Phellodendri carries out percolation, collect percolate, percolate is concentrated into 0.1 times of weight portion to 3 times weight portion of Radix Scutellariae and the dry medical material of Cortex Phellodendri, obtain dry extract II after concentrated solution is carried out drying, dry extract II is crushed to 100 order to 200 orders and obtains powder II, 4th step, obtains mixed powder by powder I and powder II mix homogeneously, 5th step, after fully being mixed homogeneously by mixed powder, obtains burn compound medicines with the adjuvant taken in the first step.
The polypharmaceutic preparation method of 11. burn according to claim 10, it is characterized in that adjuvant is carbomer, tragcanth, Polyethylene Glycol, sodium carboxymethyl cellulose, polyvinylpyrrolidone, hydroxypropyl emthylcellulose, hydroxypropyl cellulose, tristerin, glyceryl monostearate, stearic acid, tween 80, white vaseline, liquid paraffin, Cera Flava, triethanolamine, polyvinyl alcohol, arabic gum gelatin, glycerol, sodium benzoate, methyl hydroxybenzoate, ethyl hydroxybenzoate, propyl hydroxybenzoate, one in potassium sorbate, or it is wherein multiple by any mixture than composition.
12. polypharmaceutic preparation methoies of burn according to claim 10 or 11, obtain dry extract I after the concentrated solution that it is characterized in that in second step carries out vacuum drying or spraying dry, baking temperature is 40 DEG C to 150 DEG C.
13. polypharmaceutic preparation methoies of burn according to claim 10 or 11, obtain dry extract II after the concentrated solution that it is characterized in that in the 3rd step carries out vacuum drying or spraying dry, baking temperature is 40 DEG C to 140 DEG C.
The polypharmaceutic preparation method of 14. burn according to claim 12, obtain dry extract II after the concentrated solution that it is characterized in that in the 3rd step carries out vacuum drying or spraying dry, baking temperature is 40 DEG C to 140 DEG C.
15. polypharmaceutic preparation methoies of burn according to claim 10 or 11, is characterized in that this burn compound medicines to make gel or ointment or membrane or powder.
The polypharmaceutic preparation method of 16. burn according to claim 12, is characterized in that this burn compound medicines to make gel or ointment or membrane or powder.
The polypharmaceutic preparation method of 17. burn according to claim 13, is characterized in that this burn compound medicines to make gel or ointment or membrane or powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210571147.7A CN103110818B (en) | 2012-12-25 | 2012-12-25 | Compound medicinal powder for burning and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210571147.7A CN103110818B (en) | 2012-12-25 | 2012-12-25 | Compound medicinal powder for burning and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103110818A CN103110818A (en) | 2013-05-22 |
| CN103110818B true CN103110818B (en) | 2015-05-13 |
Family
ID=48409225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210571147.7A Expired - Fee Related CN103110818B (en) | 2012-12-25 | 2012-12-25 | Compound medicinal powder for burning and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103110818B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104208268A (en) * | 2014-10-03 | 2014-12-17 | 蒋世芬 | Internal traditional Chinese medicine for treating acute traumatic skin injury |
| CN106963808A (en) * | 2017-05-26 | 2017-07-21 | 威海美迪森医疗器械有限公司 | A kind of burn-scald medicine compositions and its preparation method and application |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1268365C (en) * | 2004-07-14 | 2006-08-09 | 郭泗木 | Ointment for treating burns and scalds and its preparation |
| CN1899518A (en) * | 2006-07-13 | 2007-01-24 | 李先奇 | External use Chinese medicine for treating burn and scold and its preparing method |
| CN101129787A (en) * | 2006-08-21 | 2008-02-27 | 王开贞 | Burn cream |
-
2012
- 2012-12-25 CN CN201210571147.7A patent/CN103110818B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1268365C (en) * | 2004-07-14 | 2006-08-09 | 郭泗木 | Ointment for treating burns and scalds and its preparation |
| CN1899518A (en) * | 2006-07-13 | 2007-01-24 | 李先奇 | External use Chinese medicine for treating burn and scold and its preparing method |
| CN101129787A (en) * | 2006-08-21 | 2008-02-27 | 王开贞 | Burn cream |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103110818A (en) | 2013-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102416023B (en) | Periplaneta Americana L. gel externally applied medicinal composition and preparation method and use thereof in preparation of externally applied medicines for treating scalding | |
| Ma et al. | Evaluation of wound healing effect of punica granatum L Peel extract on deep second-degree burns in rats | |
| CN111588815B (en) | External acne-removing traditional Chinese medicine composition, application thereof and acne-removing balancing essence containing composition | |
| CN105250696A (en) | Traditional Chinese medicine gel capable of promoting skin wound to heal and preparation method of traditional Chinese medicine gel | |
| CN103110818B (en) | Compound medicinal powder for burning and preparation method thereof | |
| CN104940225A (en) | Medicine capable of dissolving and eliminating lesion tissues and pathogens | |
| CN101797334B (en) | External ointment for treating onychomycosis and paronychia | |
| CN110652558A (en) | Traditional Chinese medicine hydrogel patch for treating chemotherapeutic phlebitis and preparation method thereof | |
| CN101062085B (en) | Condyloma acuminata treating medicine | |
| CN105194330A (en) | Traditional Chinese medicine composition for promoting wound healing and preparation method of traditional Chinese medicine composition | |
| CN108403570A (en) | There are the body condensation and preparation method of improvement to pruitus caused by eczema | |
| CN105012702A (en) | Application of externally used skin generation oil in preparation of drugs for preventing or treating diabetic peripheral circulation disturbance and foot ulcer | |
| CN103169846B (en) | Skin burn-scald spraying agent and preparation method thereof | |
| CN101455657A (en) | Use of salvianolic acid A and medicine composition containing salvianolic acid A from Salia miliiorrhiza Bge. | |
| Luo et al. | Effect of Zicao ointment on second-degree burns in rats | |
| CN112294929A (en) | Gynecological traditional Chinese medicine salt lotion and preparation method and application thereof | |
| CN105998134A (en) | Chinese herbal ointment for treating and repairing skin scalds | |
| CN104523825B (en) | Spearmint essential oil is preparing the application in treating allergic skin medicine | |
| Johnson et al. | Evaluation of Ethanolic Extract of Tridax procumbens Linn on Wound Healing in Rats | |
| CN102178732B (en) | Chinese medicine nanoemulsion spraying agent for treating chronic eczema | |
| CN102178795B (en) | External medicine for treating burns and scalds and preparation method of medicine | |
| CN105963338B (en) | Prevent and treat the herbal composite of cervical erosion | |
| Cao et al. | Ginkgo paste improves tinea corporis in a guinea pig model | |
| CN105663731A (en) | Traditional Chinese medicine emulsifiable paste for treating burns and scalds and preparation method and application thereof | |
| CN105998218A (en) | Pharmaceutical composition for treating female chloasma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150513 Termination date: 20211225 |